Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.est.2c04391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between driving pressure-guided ventilation and postoperative pulmonary complications in surgical patients: dealing with zero-events in evidence synthesis. Comment on Br J Anaesth 2024; 133: 647-57.
Br J Anaesth
March 2025
Department of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China; Central Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang, China. Electronic address:
Comment on "Hypospadias risk associated with chronic hypertension during pregnancy: A systematic review and meta-analysis".
J Pediatr Urol
February 2025
Department of Paediatrics, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, 411018, Maharashtra, India; Department of Public Health Dentistry, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, 411018, Maharashtra, India. Electronic address:
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
February 2025
Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Importance: Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD+, resulting in an increase of cellular adenosine triphosphate production.
Objective: To determine the effects of CNM-Au8 on ALS disease progression.
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
February 2025
Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.
Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in ALS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!